Verastem presents LGSOC drug data at IGCS 2026 meeting

Verastem Oncology (Nasdaq: VSTM) presented new analyses from its Phase 2 RAMP 201 clinical trial of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer (LGSOC) at the International Gynecologic Cancer Society 2026 Annual Global Meeting in Montréal, Canada, on October 2, 2026.

A molecular profiling analysis of baseline tumor samples examined the drug combination's activity in KRAS wild-type LGSOC subgroups. Among patients with KRAS wild-type tumors who also lacked NRAS and BRAF mutations — described as triple wild-type — the combination showed a confirmed objective response rate (ORR) of 18% and a median progression-free survival of 13 months. In patients with KRAS wild-type tumors carrying NRAS or BRAF mutations, the confirmed ORR was 22%.

Professor Susana Banerjee of The Royal Marsden NHS Foundation Trust and Global Lead Principal Investigator of the RAMP 201 trial noted that patients with triple wild-type tumors have historically experienced response rates under 10% with trametinib, chemotherapy, or endocrine therapy.

A separate external control arm analysis compared RAMP 201 outcomes against a matched cohort from the GOG 281 trial receiving conventional care. In KRAS-mutated LGSOC, weighted ORR was 38.7% with the combination versus 0% with conventional care, and median weighted progression-free survival was 22.1 months versus 6.5 months. In KRAS wild-type LGSOC, weighted ORR was 22.7% versus 7.9%, and median weighted PFS was 11.3 months versus 7.7 months.

An encore presentation of the RAMP 201J Phase 2 study in Japanese patients was also featured. Among 16 efficacy-evaluable patients with a median follow-up of 12.4 months, the combination achieved a 44% ORR and 94% disease control rate. ORRs were 71% in KRAS-mutated patients and 22% in KRAS wild-type patients.

The FDA approved avutometinib plus defactinib, marketed as Avmapki Fakzynja Co-Pack, in May 2025 for adult patients with KRAS-mutated recurrent LGSOC who have received prior systemic therapy, under accelerated approval. A Phase 3 confirmatory trial, RAMP 301, is ongoing.

You May Also Be Interested In

• Teknova and Pluristyx file FDA drug master file for PluriFreeze system
• Freedom Broker Upgrades Nike (NKE) to Buy
• Toshiba plans to double AI data center hard drive production, Evercore comments